Community Access National Network (CANN) will present its annual report on the state of HIV/HCV co-infection in the United States, including a summary of the HIV/HCV Co-Infection Watch, as well as the impact from COVID-19. The COVID-19 outbreak in the U.S. has exposed to many people, for the first, the inherent weaknesses that exist in our national healthcare system. From concerns about treatment coverage to widespread surveillance failures, this pandemic has demonstrated that, for most of the U.S., both federal and state governments have failed to invest in modernization, rural health, and surveillance infrastructure. This facilitated, multi-disciplinary panel discussion will focus on current data, real-world examples, and practical strategies for covering HCV cure therapies, federal and local harm reduction laws and policies, and the impact of COVID-19 on HIV and HCV transmission and services.

Learning Objectives:

  1. Summarize key findings from the 5th Annual National Monitoring Report on HIV/HCV Co-Infection.

  2. Identify implications of the COVID-19 pandemic on HCV and harm reduction services, HCV treatment coverage and HCV treatment adherence.

  3. List specific considerations and impacts on rural health and rural providers serving people living with, or at risk for, HIV and/or HCV.